Eli Lilly Shares Jump After GLP-1 Pill Trial Success

INDIANAPOLIS, Aug. 26, 2025 - Eli Lilly and Company (NYSE: LLY) stock surged in premarket trading Tuesday after the company announced positive late-stage trial results for its experimental oral GLP-1 therapy, orforglipron. Shares climbed roughly 2.4% to $712, up from Monday’s close of $695.33.

Lilly reported that overweight adults with type 2 diabetes receiving the highest dose of orforglipron lost an average of 10.5% of their body weight and that 75% of participants achieved A1C levels at or below 6.5%, outperforming the American Diabetes Association’s target. The safety profile was consistent with existing injectable GLP-1 treatments, with mostly mild‐to‐moderate gastrointestinal side effects.

Orforglipron, a once-daily small-molecule tablet, offers advantages over current injectables-including simpler manufacturing and no dietary restrictions-potentially enabling “extraordinary scale” production, Lilly executives said. The company plans global regulatory submissions later this year based on the ATTAIN-2 trial’s topline data.

Analysts view this development as a strategic win in the competitive diabetes and obesity market. Following the announcement, several brokerages reiterated buy ratings, citing Lilly’s robust pipeline and the growing demand for oral GLP-1 treatments. Market watchers will next focus on FDA interactions and the timing of formal submission packages.

Key Stock Data

• Prior close (Aug. 25, 2025): $695.33
• Premarket (Aug. 26, 2025): $712.00 (+2.4%)
• 52-week range: $625.65 - $960.02

About Eli Lilly Founded in 1876 and headquartered in Indianapolis, Eli Lilly & Company is a global pharmaceutical leader specializing in diabetes, oncology, immunology and neurosciences. The company has a market capitalization exceeding $650 billion and recently strengthened its cardiometabolic portfolio through strategic partnerships and clinical successes.